Literature DB >> 19544364

Impact of the number of resected and involved lymph nodes on esophageal cancer survival.

Yi-Jen Chen1, Timothy E Schultheiss, Jeffrey Y C Wong, Kemp H Kernstine.   

Abstract

BACKGROUND: Using a large data set, we investigated the impact of the number of resected and involved lymph nodes on overall survival for patients with esophageal cancer.
METHODS: From the National Oncology Database, esophageal cancer cases with data available on the total number of resected and involved nodes as well as other variables were evaluated as it relates to overall survival by multivariate analysis using Cox proportional hazards method. Patients with 0, exactly 1 or 1-3 positive nodes were separately studied to determine the association between the number of lymph nodes resected and overall survival.
RESULTS: From 1969 to 2002, 3,144 (17%) of 18,390 esophageal cancer cases with complete data were identified. Increasing number of involved nodes predicted poorer outcome (P < 10(-6)). Results from studying patients with 0, exactly 1 or 1-3 positive nodes showed that survival improved with increasing number of nodes analyzed up to 12. Three-tier nodal grouping with increasing risk of death were identified, 0, 1-3, and >or=4 positive nodes (P < 10(-5)).
CONCLUSIONS: The pathological assessment of minimal 12 lymph nodes provides sufficient prognostic information. Three-tier nodal grouping is suggested for the next version of AJCC staging system for esophageal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19544364     DOI: 10.1002/jso.21312

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

Review 1.  The significance of lymph node status as a prognostic factor for esophageal cancer.

Authors:  Yasunori Akutsu; Hisahiro Matsubara
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

2.  Oesophageal squamous cell carcinoma: relationship between fluorine-18 fludeoxyglucose positron emission tomography CT maximum standardised uptake value, metabolic tumour volume, and tumour, node and metastasis classification.

Authors:  W-Q Zhu; X Sun; L Xing; M Li; J Yue; W Qu; X Sun; L Kong; J Yu
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

3.  Role of Recurrent Laryngeal Nerve Lymph Node Dissection in Surgery of Early-Stage Esophageal Squamous Cell Carcinoma.

Authors:  Tae Hee Hong; Hong Kwan Kim; Genehee Lee; Sumin Shin; Jong Ho Cho; Yong Soo Choi; Jae Ill Zo; Young Mog Shim
Journal:  Ann Surg Oncol       Date:  2021-09-03       Impact factor: 5.344

4.  Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes.

Authors:  San-Gang Wu; Jia-Yuan Sun; Li-Chao Yang; Juan Zhou; Feng-Yan Li; Qun Li; Huan-Xin Lin; Qin Lin; Zhen-Yu He
Journal:  Oncotarget       Date:  2015-11-03

5.  Achieving adequate lymph node dissection in treating esophageal squamous cell carcinomas by radical lymphadenectomy: Beyond the scope of numbers of harvested lymph nodes.

Authors:  Zheng Lin; Weilin Chen; Yuanmei Chen; Xiane Peng; Siyou Yan; Fei He; Rong Fu; Yixian Jiang; Zhijian Hu
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

6.  Survival risk prediction model for patients with pT1-3 N0M0 esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.

Authors:  Zhan Qi; Yuanping Hu; Rong Qiu; Juan Li; Yuekao Li; Ming He; Yuxiang Wang
Journal:  J Cardiothorac Surg       Date:  2021-05-01       Impact factor: 1.522

7.  Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes.

Authors:  Qun Li; San-Gang Wu; Jian-Ming Gao; Jun-Jie Xu; Lian-Ying Hu; Tao Xu
Journal:  J Radiat Res       Date:  2012-11-02       Impact factor: 2.724

8.  Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer.

Authors:  Sanchuan Lai; Tingting Su; Xingkang He; Zhenghua Lin; Shujie Chen
Journal:  Oncotarget       Date:  2017-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.